Hologic, a global leader in women’s health, has announced a definitive agreement to acquire Reveal Genomics. The financial details of the acquisition were not disclosed. Reveal Genomics is a privately held company focused on post-operative biomarker testing for endometriosis. This acquisition will expand Hologic's offerings in the women's health space, particularly in diagnostics. Hologic intends to combine Reveal Genomics’ technology with its existing portfolio to provide more comprehensive solutions for women experiencing endometriosis. The deal is expected to close in Hologic’s fourth fiscal quarter, subject to customary closing conditions. This move underscores Hologic’s commitment to innovation and addressing unmet needs in women’s healthcare.